Seattle Genetics, Takeda announce data from analysis of PFS with ADCETRIS Takeda Pharmaceutical and Seattle Genetics announced data from a post-hoc analysis examining progression-free survival, PFS, following treatment with ADCETRIS versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma post-autologous stem ... (more)
http://www.theflyonthewall.com/permalinks/entry.php/SGENid1848462/SGEN-Seattle-Genetics-Takeda-announce-data-from-analysis-of-PFS-with-ADCETRIS
http://www.theflyonthewall.com/permalinks/entry.php/SGENid1848462/SGEN-Seattle-Genetics-Takeda-announce-data-from-analysis-of-PFS-with-ADCETRIS
No comments:
Post a Comment